The bad news is it was on bardoxolone. Tweetorial catch-up here.
The CARDINAL Visual Abstract
Does Bardoxolone help patients with Alport’s Syndrome? Dr M Abdul Qader explains graphically.
Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
The bad news is it was on bardoxolone. Tweetorial catch-up here.
✳️ #TenTweetNephJC ✳️
— Nephrology Journal Club (@NephJC) January 28, 2023
This week CARDINAL - the largest ever RCT in patients with Alport Syndrome 🧵👇 pic.twitter.com/wrAxJoz1GJ
Does Bardoxolone help patients with Alport’s Syndrome? Dr M Abdul Qader explains graphically.